What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2022-08-11 compared with 2022-05-12 · 45 added, 8 removed, 110 unchanged (33% of the section changed)

ITEM 1A – RISK FACTORS

ITEM 1A – RISK

There have been no material changes to the risk

23 unchanged sentences

will depend on a number of factors, including:

· Funding the costs relating to the research and development, regulatory approval,

commercialization and sale and marketing of our drug candidates and technologies;

Funding the costs relating to the research and development, regulatory approval, commercialization and sale and marketing of our drug candidates and technologies;

Market acceptance of our drug candidates and technologies;

7 unchanged sentences

Our ability to raise additional capital.

As of March 31, 2022, we had an accumulated deficit

As of June 30, 2022, we had an accumulated deficit

of approximately $186.8 million.

73 unchanged sentences

do not have sufficient funds, we may not be able to further develop our drug candidates or bring them to market and generate product revenue.

ITEM 2 – UNREGISTERED SALES OF EQUITY

SECURITIES AND USE OF PROCEEDS

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

ITEM 4 – MINE SAFETY DISCLOSURES

Risks Related to Our Common Stock

Our failure to meet the continued listing

requirements of The Nasdaq Capital Market could result in a de-listing of our common stock.

Failure to regain compliance with Nasdaq listing

rules could affect the market price of our Common Stock and liquidity and reduce our ability to raise capital.

Currently, our Common Stock trades on the Nasdaq

Capital Market.

On June 3, 2022, the Company received a written notification (the “Notice”) from the Listing Qualifications

Department of the NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for its common stock

had been below $1.00 for 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement

for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”).

Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market.

Under the Nasdaq Listing Rules, the Company has

a period of 180 calendar days from the date of the Notice to regain compliance with the Bid Price Requirement.

Accordingly, the Company

has until November 30, 2022 (the "Compliance Date"), to regain compliance with the Bid Price Requirement.

To regain compliance,

the closing bid price of the Company's common stock must be at least $1.00 for a minimum of ten consecutive business days prior to the

Compliance Date.

In the event the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional

180 calendar day compliance period.

To qualify for this second compliance period, the Company will be required to meet the continued listing

requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception

of the Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance

period, by effecting a reverse stock split, if necessary.

The Company intends to monitor the closing bid

price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement.

there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement, or will otherwise be in compliance

with other Nasdaq Listing Rules.

If we fail to regain compliance with the Nasdaq Listing Rules, including the Bid Price Requirement, we

could be delisted and our stock would be considered a penny stock under regulations of the SEC, and would therefore be subject to rules

that impose additional sales practice requirements on broker-dealers who sell our securities.

The additional burdens imposed upon broker-dealers

by these requirements could discourage broker-dealers from effecting transactions in our common stock, which could severely limit the

market liquidity of our common stock and stockholder’s ability to sell our securities in the secondary market.

If our common

stock were to be delisted from the NASDAQ Capital Market, the liquidity of our common stock would be materially affected, which would

decrease the attractiveness of our common stock to investors and result in a decline in the market price of our common stock.

may be difficult for us to raise additional capital if we are not listed on a major exchange.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 3 – DEFAULTS UPON SENIOR

ITEM 4 – MINE SAFETY

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors